{"id":"moxifloxacin-prednisolone-combination","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased intraocular pressure"},{"rate":"null","effect":"Cataract"},{"rate":"null","effect":"Glaucoma"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Moxifloxacin works by binding to the bacterial enzymes DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription. Prednisolone, on the other hand, reduces inflammation by inhibiting the production of pro-inflammatory mediators such as prostaglandins and leukotrienes. This combination of mechanisms makes moxifloxacin/prednisolone effective against bacterial infections and inflammation.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while prednisolone is a corticosteroid that reduces inflammation by inhibiting phospholipase A2 and other enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:06.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Uveitis"}]},"trialDetails":[{"nctId":"NCT06681688","phase":"PHASE1, PHASE2","title":"Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC","status":"RECRUITING","sponsor":"Inder Paul Singh, M.D.","startDate":"2024-07-10","conditions":"Cataract","enrollment":94},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT01603030","phase":"PHASE3","title":"Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation","status":"UNKNOWN","sponsor":"Adapt Produtos Oftalmológicos Ltda.","startDate":"2012-06","conditions":"Eye Infection/Inflammation Other","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["moxifloxacin 0,5%; predfort"],"phase":"phase_3","status":"active","brandName":"moxifloxacin/prednisolone combination","genericName":"moxifloxacin/prednisolone combination","companyName":"Adapt Produtos Oftalmológicos Ltda.","companyId":"adapt-produtos-oftalmol-gicos-ltda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while prednisolone is a corticosteroid that reduces inflammation by inhibiting phospholipase A2 and other enzymes. Used for Bacterial conjunctivitis, Uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}